1
|
Zhang Y, Zhao Y, An C, Guo Y, Ma Y, Shao F, Zhang Y, Sun K, Cheng F, Ren C, Zhang L, Sun B, Zhang Y, Wang H. Material-driven immunomodulation and ECM remodeling reverse pulmonary fibrosis by local delivery of stem cell-laden microcapsules. Biomaterials 2024; 313:122757. [PMID: 39178558 DOI: 10.1016/j.biomaterials.2024.122757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2024] [Revised: 08/13/2024] [Accepted: 08/15/2024] [Indexed: 08/26/2024]
Abstract
Recent progress in stem cell therapy has demonstrated the therapeutic potential of intravenous stem cell infusions for treating the life-threatening lung disease of pulmonary fibrosis (PF). However, it is confronted with limitations, such as a lack of control over cellular function and rapid clearance by the host after implantation. In this study, we developed an innovative PF therapy through tracheal administration of microfluidic-templated stem cell-laden microcapsules, which effectively reversed the progression of inflammation and fibrotic injury. Our findings highlight that hydrogel microencapsulation can enhance the persistence of donor mesenchymal stem cells (MSCs) in the host while driving MSCs to substantially augment their therapeutic functions, including immunoregulation and matrix metalloproteinase (MMP)-mediated extracellular matrix (ECM) remodeling. We revealed that microencapsulation activates the MAPK signaling pathway in MSCs to increase MMP expression, thereby degrading overexpressed collagen accumulated in fibrotic lungs. Our research demonstrates the potential of hydrogel microcapsules to enhance the therapeutic efficacy of MSCs through cell-material interactions, presenting a promising yet straightforward strategy for designing advanced stem cell therapies for fibrotic diseases.
Collapse
Affiliation(s)
- Yujie Zhang
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China
| | - Yuan Zhao
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China
| | - Chuanfeng An
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China
| | - Yiyang Guo
- State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, PR China; School of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, 116024, Dalian, PR China
| | - Yubin Ma
- State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, PR China; School of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, 116024, Dalian, PR China
| | - Fei Shao
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China
| | - Yonggang Zhang
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China
| | - Kai Sun
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China
| | - Fang Cheng
- State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, PR China
| | - Changle Ren
- Faculty of Medicine, Dalian University of Technology, Dalian, 116023, PR China; Department of Joint Surgery, Dalian Municipal Central Hospital, Dalian, 116044, PR China
| | - Lijun Zhang
- Third People's Hospital of Dalian, Dalian Eye Hospital, Dalian, 116024, PR China
| | - Bingbing Sun
- State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, PR China; School of Chemical Engineering, Dalian University of Technology, 2 Linggong Road, 116024, Dalian, PR China
| | - Yang Zhang
- School of Dentistry, Health Science Center, Shenzhen University, Shenzhen, 518015, PR China
| | - Huanan Wang
- MOE Key Laboratory of Bio-Intelligent Manufacturing, Dalian Key Laboratory of Artificial Organ and Regenerative Medicine, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, PR China; State Key Laboratory of Fine Chemicals, Frontiers Science Center for Smart Materials Oriented Chemical Engineering, Dalian University of Technology, Dalian, 116024, PR China.
| |
Collapse
|
2
|
Ju Y, Yi L, Li C, Wang T, Zhang W, Chai W, Yin X, Weng T. Comparison of biological characteristics of human adipose- and umbilical cord- derived mesenchymal stem cells and their effects on delaying the progression of osteoarthritis in a rat model. Acta Histochem 2022; 124:151911. [DOI: 10.1016/j.acthis.2022.151911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 05/19/2022] [Accepted: 05/22/2022] [Indexed: 11/25/2022]
|
3
|
Hou W, Duan L, Huang C, Li X, Xu X, Qin P, Hong N, Wang D, Jin W. Cross-Tissue Characterization of Heterogeneities of Mesenchymal Stem Cells and Their Differentiation Potentials. Front Cell Dev Biol 2021; 9:781021. [PMID: 34977025 PMCID: PMC8719164 DOI: 10.3389/fcell.2021.781021] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 11/18/2021] [Indexed: 12/28/2022] Open
Abstract
Mesenchymal stem/stromal cells (MSCs) are promising cell sources for regenerative medicine and the treatment of autoimmune disorders. Comparing MSCs from different tissues at the single-cell level is fundamental for optimizing clinical applications. Here we analyzed single-cell RNA-seq data of MSCs from four tissues, namely umbilical cord, bone marrow, synovial tissue, and adipose tissue. We identified three major cell subpopulations, namely osteo-MSCs, chondro-MSCs, and adipo/myo-MSCs, across all MSC samples. MSCs from the umbilical cord exhibited the highest immunosuppression, potentially indicating it is the best immune modulator for autoimmune diseases. MSC subpopulations, with different subtypes and tissue sources, showed pronounced differences in differentiation potentials. After we compared the cell subpopulations and cell status pre-and-post chondrogenesis induction, osteogenesis induction, and adipogenesis induction, respectively, we found MSC subpopulations expanded and differentiated when their subtypes consist with induction directions, while the other subpopulations shrank. We identified the genes and transcription factors underlying each induction at the single-cell level and subpopulation level, providing better targets for improving induction efficiency.
Collapse
Affiliation(s)
- Wenhong Hou
- Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China
| | - Li Duan
- Department of Orthopedics, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
- Shenzhen Institute of Geriatircs, Shenzhen, China
| | - Changyuan Huang
- Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China
- School of Life Science and Technology, Harbin Institute of Technology, Harbin, China
| | - Xingfu Li
- Department of Orthopedics, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
| | - Xiao Xu
- Department of Orthopedics, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
| | - Pengfei Qin
- Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China
| | - Ni Hong
- Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China
| | - Daping Wang
- Department of Orthopedics, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China
- *Correspondence: Daping Wang, ; Wenfei Jin,
| | - Wenfei Jin
- Shenzhen Key Laboratory of Gene Regulation and Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China
- *Correspondence: Daping Wang, ; Wenfei Jin,
| |
Collapse
|
4
|
Tsai SCS, Yang KD, Chang KH, Lin FCF, Chou RH, Li MC, Cheng CC, Kao CY, Chen CP, Lin HC, Hsu YC. Umbilical Cord Mesenchymal Stromal Cell-Derived Exosomes Rescue the Loss of Outer Hair Cells and Repair Cochlear Damage in Cisplatin-Injected Mice. Int J Mol Sci 2021; 22:ijms22136664. [PMID: 34206364 PMCID: PMC8267798 DOI: 10.3390/ijms22136664] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Revised: 06/10/2021] [Accepted: 06/12/2021] [Indexed: 12/21/2022] Open
Abstract
Umbilical cord-derived mesenchymal stromal cells (UCMSCs) have potential applications in regenerative medicine. UCMSCs have been demonstrated to repair tissue damage in many inflammatory and degenerative diseases. We have previously shown that UCMSC exosomes reduce nerve injury-induced pain in rats. In this study, we characterized UCMSC exosomes using RNA sequencing and proteomic analyses and investigated their protective effects on cisplatin-induced hearing loss in mice. Two independent experiments were designed to investigate the protective effects on cisplatin-induced hearing loss in mice: (i) chronic intraperitoneal cisplatin administration (4 mg/kg) once per day for 5 consecutive days and intraperitoneal UCMSC exosome (1.2 μg/μL) injection at the same time point; and (ii) UCMSC exosome (1.2 μg/μL) injection through a round window niche 3 days after chronic cisplatin administration. Our data suggest that UCMSC exosomes exert protective effects in vivo. The post-traumatic administration of UCMSC exosomes significantly improved hearing loss and rescued the loss of cochlear hair cells in mice receiving chronic cisplatin injection. Neuropathological gene panel analyses further revealed the UCMSC exosomes treatment led to beneficial changes in the expression levels of many genes in the cochlear tissues of cisplatin-injected mice. In conclusion, UCMSC exosomes exerted protective effects in treating ototoxicity-induced hearing loss by promoting tissue remodeling and repair.
Collapse
Affiliation(s)
- Stella Chin-Shaw Tsai
- Department of Otolaryngology, Tungs’ Taichung Metroharbor Hospital, Taichung 435, Taiwan;
- Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, 145, Guoguang Rd., South Dist., Taichung City 402, Taiwan
| | - Kuender D. Yang
- Department of Medical Research, Mackay Memorial Hospital, Taipei 104, Taiwan; (K.D.Y.); (C.-P.C.)
- Department of Otolaryngology, Mackay Memorial Hospital, New Taipei City 251, Taiwan
| | - Kuang-Hsi Chang
- Department of Medical Research, Tungs’ Taichung Metroharbor Hospital, Taichung 435, Taiwan;
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406, Taiwan;
- General Education Center, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan
| | - Frank Cheau-Feng Lin
- Department of Thoracic Surgery, Chung Shan Medical University Hospital, Taichung 402, Taiwan;
- School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
| | - Ruey-Hwang Chou
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406, Taiwan;
- Center for Molecular Medicine, China Medical University Hospital, Taichung 406, Taiwan
- Department of Medical Laboratory and Biotechnology, Asia University, Taichung 413, Taiwan
| | - Min-Chih Li
- Institute of Biomedical Sciences, Mackay Medical College, New Taipei City 252, Taiwan;
| | - Ching-Chang Cheng
- Laboratory Animal Service Center, Office of Research and Development, China Medical University, Taichung 406, Taiwan;
| | - Chien-Yu Kao
- Medical and Pharmaceutical Industry Technology and Development Center, New Taipei City 248, Taiwan;
| | - Chie-Pein Chen
- Department of Medical Research, Mackay Memorial Hospital, Taipei 104, Taiwan; (K.D.Y.); (C.-P.C.)
| | - Hung-Ching Lin
- Department of Audiology and Speech-Language Pathology, Mackay Medical College, New Taipei City 252, Taiwan;
| | - Yi-Chao Hsu
- Institute of Biomedical Sciences, Mackay Medical College, New Taipei City 252, Taiwan;
- Department of Audiology and Speech-Language Pathology, Mackay Medical College, New Taipei City 252, Taiwan;
- Correspondence: ; Tel.: +886-2-26360303 (ext. 1721)
| |
Collapse
|
5
|
Putra A, Alif I, Hamra N, Santosa O, Kustiyah AR, Muhar AM, Lukman K. MSC-released TGF-β regulate α-SMA expression of myofibroblast during wound healing. J Stem Cells Regen Med 2020; 16:73-79. [PMID: 33414583 DOI: 10.46582/jsrm.1602011] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 10/14/2020] [Indexed: 12/27/2022]
Abstract
Objective: Wound healing without fibrosis remains a clinical challenge and a new strategy to promote the optimal wound healing is needed. Mesenchymal stem cells (MSCs) can completely regenerate tissue injury due to the robust MSCs ability in controlling inflammation niche leading to granulation tissue formation, particularly through a release of various growth factors including transforming growth factor-β (TGF-β). In response to TGF-β stimulation, fibroblasts differentiate into myofibroblast, marked by alpha-smooth muscle actin (α-SMA) that leads to wound healing acceleration. On the other hand, sustained activation of TGF-β in wound areas may contribute to fibrosis-associated scar formation. The aim of this study was to evaluate the α-SMA expression of myofibroblast induced by MSC-released TGF-β during wound healing process. Materials and Methods: Twenty-four full-thickness excisional rat wound models were randomly divided into four groups: sham (Sh), Control (C), and MSCs treatment groups; topically treated by the MSCs at doses 2x106 cells (T1) and 1x106 cells (T2), respectively. While the control group was treated with NaCl. TGF-β level was determined using ELISA assay, α-SMA expression of myofibroblast was analyzed by immunofluorescence staining, and wound size measurement was calculated using a standard caliper. Results: This study showed a significant increase in TGF-β levels in all treatment groups on days 3 and 6. This finding was consistent with a significant increase of α-SMA expression of myofibroblast at day 6 and wound closure percentage, indicating that MSCs might promote an increase of wound closure. Conclusion: MSCs regulated the release of TGF-β to induce α-SMA expression of myofibroblast for accelerating an optimal wound healing.
Collapse
Affiliation(s)
- Agung Putra
- Stem Cell And Cancer Research (SCCR), Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia.,Department of Postgraduate Biomedical Science, Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia.,Department of Pathological Anatomy, Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia
| | - Iffan Alif
- Stem Cell And Cancer Research (SCCR), Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia
| | - Nurfitriani Hamra
- Postgraduate Biomedical Student, Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia
| | - Octyana Santosa
- Medical Student, Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia
| | - Azizah Retno Kustiyah
- Department of Pediatric, Medical Faculty, Universitas Islam Sultan Agung (UNISSULA), Semarang, Central Java, Indonesia
| | - Adi Muradi Muhar
- Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara (USU), Medan, Indonesia
| | - Kiki Lukman
- Department of Surgery, Faculty of Medicine, Universitas Padjadjaran (UNPAD), Bandung,West Java, Indonesia
| |
Collapse
|
6
|
Meng MY, Li L, Wang WJ, Liu FF, Song J, Yang SL, Tan J, Gao H, Zhao YY, Tang WW, Han R, Zhu K, Liao LW, Hou ZL. Assessment of tumor promoting effects of amniotic and umbilical cord mesenchymal stem cells in vitro and in vivo. J Cancer Res Clin Oncol 2019; 145:1133-1146. [PMID: 30805774 PMCID: PMC6482126 DOI: 10.1007/s00432-019-02859-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Accepted: 02/07/2019] [Indexed: 12/30/2022]
Abstract
Purpose Human mesenchymal stem cells (hMSCs) have been applied in a variety of therapies recently. However, the role of MSCs in tumor progression remains largely elusive. Some studies demonstrated that MSCs can promote tumor growth, while others had opposite results. Therefore, the lack of evidence about the effect of MSCs on tumor cells impedes its further use. Methods In the current study, hMSCs from amniotic membrane (hAMSCs) and umbilical cord (hUCMSCs) were used to evaluate the effects of MSCs on tumor development in vitro and in vivo. Two different animal models based on subcutaneous xenograft bearing nude mice and a murine experimental metastatic model were established for in vivo study. Moreover, cytokines regulated by MSCs co-cultured with cancer cells SPC-A-1 were also analyzed by cytokine array. Results Our results indicated that hUCMSCs not only did not promote proliferation in cancer cells, but also inhibited migration. In addition, they inhibited tube formation in human umbilical vein endothelial cells (HUVECs). Although hAMSCs also showed inhibitory effects on cancer cell motility, the proliferation of cancer cells was indeed enhanced. The in vivo data revealed that hUCMSCs did not promote tumor progression in lung adenocarcinoma and gastric carcinoma xenografts. Nevertheless, hAMSCs could do. The results from murine experimental metastatic model also demonstrated that neither hUCMSCs nor hAMSCs significantly enhanced the lung metastasis. The data from cytokine array showed that 11 inflammatory factors, 8 growth factors and 11 chemokines were remarkably secreted and changed. Conclusions In view of the data from in vitro and in vivo studies, the exploitation of hUCMSCs in new therapeutic strategies should be safe compared to hAMSCs under malignant conditions. Moreover, this is the first report to systematically elucidate the possible molecular mechanisms involved in UCMSC- and AMSC-affected tumor growth and metastasis. Electronic supplementary material The online version of this article (10.1007/s00432-019-02859-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ming-Yao Meng
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan, People's Republic of China
| | - Lin Li
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan, People's Republic of China
| | - Wen-Ju Wang
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan, People's Republic of China
| | - Fei-Fei Liu
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Jian Song
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Song-Lin Yang
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Jing Tan
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China
| | - Hui Gao
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China
| | - Yi-Yi Zhao
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China
| | - Wei-Wei Tang
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China
| | - Rui Han
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Kai Zhu
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China.,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China.,Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Li-Wei Liao
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China. .,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China. .,Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan, People's Republic of China.
| | - Zong-Liu Hou
- Central Laboratory of Yan'an Hospital Affiliated to Kunming Medical University, No. 245 East of Renmin Road, Kunming, 650051, Yunnan, People's Republic of China. .,Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan, People's Republic of China. .,Yunnan Cell Biology and Clinical Translation Research Center, Kunming, Yunnan, People's Republic of China.
| |
Collapse
|
7
|
Pu L, Meng M, Wu J, Zhang J, Hou Z, Gao H, Xu H, Liu B, Tang W, Jiang L, Li Y. Compared to the amniotic membrane, Wharton's jelly may be a more suitable source of mesenchymal stem cells for cardiovascular tissue engineering and clinical regeneration. Stem Cell Res Ther 2017; 8:72. [PMID: 28320452 PMCID: PMC5359832 DOI: 10.1186/s13287-017-0501-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 01/23/2017] [Accepted: 02/09/2017] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND The success of developing cardiovascular tissue engineering (CTE) grafts greatly needs a readily available cell substitute for endothelial and interstitial cells. Perinatal annexes have been proposed as a valuable source of mesenchymal stem cells (MSCs) for tissue engineering and regenerative medicine. The objective of the present study is to evaluate the potential of human Wharton's jelly MSCs (WJ-MSCs) and amniotic membrane MSCs (AM-MSCs) as a seeding cell in CTE and cardiovascular regenerative medicine. METHODS WJ-MSCs/AM-MSCs were isolated and characterized in vitro according to their morphology, proliferation, self-renewal, phenotype, and multipotency. More importantly, the characteristics of hemocompatibility, extracellular matrix deposition, and gene expression and viability of both MSCs were investigated. RESULTS Fibroblast-like human WJ-MSCs and AM-MSCs were successfully isolated and positively expressed the characteristic markers CD73, CD90, and CD105 but were negative for CD34, CD45, and HLA-DR. Both MSCs shared trilineage differentiation toward the adipogenic, osteogenic, and chondrogenic lineages. The proliferative and self-renewal capacity of WJ-MSCs was significantly higher than that of AM-MSCs (P < 0.001). WJ-MSCs provided comparable properties of antiplatelet adhesion and did not activate the coagulation cascade to endothelial cells. However, aggregated platelets were visualized on the surface of AM-MSCs-derived cell sheets and the intrinsic pathway was activated. Furthermore, WJ-MSCs have superior properties of collagen deposition and higher viability than AM-MSCs during cell sheet formation. CONCLUSIONS This study highlights that WJ-MSCs could act as a functional substitute of endothelial and interstitial cells, which could serve as an appealing and practical single-cell source for CTE and regenerative therapy.
Collapse
Affiliation(s)
- Lei Pu
- Department of Cardiovascular Surgery, Yan’an Affiliated Hospital of Kunming Medical University, Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Mingyao Meng
- Central Laboratory, Yan’an Affiliated Hospital of Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Jian Wu
- Department of Cardiovascular Surgery, Yan’an Affiliated Hospital of Kunming Medical University, Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
- Cardiovascular Surgery Institute of Yunnan, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Jing Zhang
- Department of Anesthesiology, The Second Affiliated Hospital of Kunming Medical University, 374, Dianmian Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Zongliu Hou
- Central Laboratory, Yan’an Affiliated Hospital of Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Hui Gao
- Central Laboratory, Yan’an Affiliated Hospital of Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Hui Xu
- Department of Thoracic Surgery, Yan’an Affiliated Hospital of Kunming Medical University, Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Boyu Liu
- Department of Cardiovascular Surgery, Yan’an Affiliated Hospital of Kunming Medical University, Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Weiwei Tang
- Central Laboratory, Yan’an Affiliated Hospital of Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| | - Lihong Jiang
- Department of Cardiovascular Surgery, Yan’an Affiliated Hospital of Kunming Medical University, Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
- Cardiovascular Surgery Institute of Yunnan, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
- First People’s Hospital of Yunnan Province, 157, Jinbi Road, Kunming, Yunnan People’s Republic of China
| | - Yaxiong Li
- Department of Cardiovascular Surgery, Yan’an Affiliated Hospital of Kunming Medical University, Kunming Medical University, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
- Cardiovascular Surgery Institute of Yunnan, 245, East of Renmin Road, Kunming, 650051 Yunnan People’s Republic of China
| |
Collapse
|
8
|
Pu L, Wu J, Pan X, Hou Z, Zhang J, Chen W, Na Z, Meng M, Ni H, Wang L, Li Y, Jiang L. Determining the optimal protocol for preparing an acellular scaffold of tissue engineered small-diameter blood vessels. J Biomed Mater Res B Appl Biomater 2017; 106:619-631. [PMID: 28271637 DOI: 10.1002/jbm.b.33827] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 10/13/2016] [Accepted: 11/22/2016] [Indexed: 12/18/2022]
Abstract
Although detergent-based decellularization protocols have been widely used to obtain a natural extracellular matrix (ECM) scaffold in tissue engineering, some key challenges still exist. To achieve an optimum natural decellularized scaffold for the construction of tissue-engineered small-diameter blood vessels (TEBV), porcine carotid arteries (PCAs) were decellularized by combining sodium dodecyl sulfate (SDS), sodium deoxycholate (SDC) and Triton X-100 (Triton) in different concentrations. Tissue samples were processed and their histological, biochemical and biomechanical characteristics were investigated. Results showed that only two methods 0.5% (SDS + SDC) and 1% (SDS + SDC) could completely remove of the cellular contents and preserve the native ECM architecture. Furthermore, 1% (SDS + SDC) based methods acquire preferable porosity and suitable mechanical strength. Residual Triton in the ECM scaffold holds intensive cytotoxity. In conclusion, 1%(SDS + SDC) based method can obtain a superior PCAs scaffold for the construction of TEBV. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 619-631, 2018.
Collapse
Affiliation(s)
- Lei Pu
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Jian Wu
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China.,Cardiovascular Surgery, Institution of Yunnan, Kunming, Yunnan, People's Republic of China
| | - Xingna Pan
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Zongliu Hou
- Central Laboratory, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Jing Zhang
- Department of Anesthesiology, Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Wenmin Chen
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China.,Cardiovascular Surgery, Institution of Yunnan, Kunming, Yunnan, People's Republic of China
| | - Zhuhui Na
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China.,Cardiovascular Surgery, Institution of Yunnan, Kunming, Yunnan, People's Republic of China
| | - Mingyao Meng
- Central Laboratory, Yan'an Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Haiyan Ni
- Department of Pathology, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Liqiong Wang
- Department of Pathology, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China
| | - Yaxiong Li
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China.,Cardiovascular Surgery, Institution of Yunnan, Kunming, Yunnan, People's Republic of China
| | - Lihong Jiang
- Cardiovascular Surgery, Yan'an Affiliated Hospital of Kunming Medical University, Kunming Medical University, Kunming, Yunnan, People's Republic of China.,Cardiovascular Surgery, Institution of Yunnan, Kunming, Yunnan, People's Republic of China
| |
Collapse
|
9
|
Xiong H, Bai C, Wu S, Gao Y, Lu T, Hu Q, Guan W, Ma Y. Biological characterization of mesenchymal stem cells from bovine umbilical cord. Anim Cells Syst (Seoul) 2014. [DOI: 10.1080/19768354.2014.880370] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
10
|
Hou ZL, Liu Y, Mao XH, Wei CY, Meng MY, Liu YH, Zhuyun Yang Z, Zhu H, Short M, Bernard C, Xiao ZC. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adh Migr 2013; 7:404-7. [PMID: 24192520 DOI: 10.4161/cam.26941] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
There is currently great interest in the use of mesenchymal stem cells as a therapy for multiple sclerosis with potential to both ameliorate inflammatory processes as well as improve regeneration and repair. Although most clinical studies have used autologous bone marrow-derived mesenchymal stem cells, other sources such as allogeneic umbilical cord-derived cells may provide a more accessible and practical supply of cells for transplantation. In this case report we present the treatment of aggressive multiple sclerosis with multiple allogenic human umbilical cord-derived mesenchymal stem cell and autologous bone marrow-derived mesenchymal stem cells over a 4 y period. The treatments were tolerated well with no significant adverse events. Clinical and radiological disease appeared to be suppressed following the treatments and support the expansion of mesenchymal stem cell transplantation into clinical trials as a potential novel therapy for patients with aggressive multiple sclerosis.
Collapse
Affiliation(s)
- Zong-liu Hou
- Yan-an Hospital; Kunming Medical University; Kunming, PR China
| | - Ying Liu
- Yan-an Hospital; Kunming Medical University; Kunming, PR China
| | - Xi-Hong Mao
- Yan-an Hospital; Kunming Medical University; Kunming, PR China
| | - Chuan-yu Wei
- Yan-an Hospital; Kunming Medical University; Kunming, PR China
| | - Ming-yao Meng
- Yan-an Hospital; Kunming Medical University; Kunming, PR China
| | - Yun-hong Liu
- Yan-an Hospital; Kunming Medical University; Kunming, PR China
| | - Zara Zhuyun Yang
- The Key Laboratory of Stem Cell and Regenerative Medicine; Institute of Molecular and Clinical Medicine; Kunming Medical College; Kunming, PR China; Department of Anatomy and Developmental Biology; Monash University; Clayton, Victoria, Australia
| | - Hongmei Zhu
- The Key Laboratory of Stem Cell and Regenerative Medicine; Institute of Molecular and Clinical Medicine; Kunming Medical College; Kunming, PR China; Department of Anatomy and Developmental Biology; Monash University; Clayton, Victoria, Australia
| | - Martin Short
- Australian Regenerative Medicine Institute; Monash University; Clayton, VIC, Australia
| | - Claude Bernard
- Department of Anatomy and Developmental Biology; Monash University; Clayton, Victoria, Australia
| | - Zhi-cheng Xiao
- The Key Laboratory of Stem Cell and Regenerative Medicine; Institute of Molecular and Clinical Medicine; Kunming Medical College; Kunming, PR China; Australian Regenerative Medicine Institute; Monash University; Clayton, VIC, Australia
| |
Collapse
|
11
|
Shi-jie Lv, Liu Y, Jian-chun Lian, He X, Liu C, Guang-wei Sun, Guo X, Xiao-jun Ma, Li H. Proliferation, Stemness and Cardiac Differentiation Properties of Umbilical Cord Wharton^|^rsquo;s Jelly-derived Mesenchymal Stem Cells during the Continuous Passages. J HARD TISSUE BIOL 2013. [DOI: 10.2485/jhtb.22.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|